Soligenix Inc. (NASDAQ: SNGX) provided an update on its Phase 3 clinical trial for HyBryte, a novel topical therapy for cutaneous T-cell lymphoma (CTCL), during a recent investment webinar. The interim results from an investigator-initiated study at the University of Pennsylvania, led by Dr. Ellen Kim, demonstrated that 75% of the first eight patients who completed 18 weeks of treatment experienced a greater than 50% reduction in disease severity. These findings underscore the potential of HyBryte as a transformative therapy for CTCL patients, particularly those with early-stage mycosis fungoides, which accounts for nearly 90% of CTCL cases.
HyBryte is a topical therapy activated by visible light and applied directly to cancerous skin lesions. It represents Soligenix's lead asset in its pipeline targeting rare diseases and unmet medical needs. The company anticipates releasing top-line results from the Phase 3 trial in the second half of 2026. For more details on the clinical development of HyBryte, visit https://ibn.fm/dz7eO.
The progress in the HyBryte clinical trial is significant as it offers hope for a new, effective treatment option for CTCL patients, who currently have limited therapeutic choices. The positive interim results not only demonstrate the therapy's potential efficacy but also highlight Soligenix's commitment to advancing treatments for rare and challenging diseases. CTCL is a rare form of non-Hodgkin's lymphoma that primarily affects the skin, and current treatment options often have limited efficacy or significant side effects. If HyBryte continues to show positive results, it could become a valuable addition to the treatment landscape for this patient population.
